0.5848

1.04% 0.006

After Hours: .57 -0.0148 -2.53%

Verrica Pharmaceuticals Inc (VRCA)

Overview News Price History Option Chain Financials Discussions Forecast

Verrica Pharmaceuticals Inc stock is traded at $0.5848, with a volume of 366.29K. It is up +1.04% in the last 24 hours and down -9.07% over the past month. Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Previous Close:

$0.5788

Open:

$0.5712

24h Volume:

366.29K

Relative Volume:

1.04

Market Cap:

$55.59M

Revenue:

$5.12M

Net Income/Loss:

$-67.00M

P/E Ratio:

-0.3978

EPS:

-1.47

Net Cash Flow:

$-38.94M

1W Performance:

-6.15%

1M Performance:

-9.07%

6M Performance:

-15.76%

1Y Performance:

-91.89%

1-Day Range:

$0.5675

$0.63

1-Week Range:

$0.5675

$0.7074

52-Week Range:

$0.3816

$8.98

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name

Verrica Pharmaceuticals Inc

Sector

Healthcare (1174)

Industry

Biotechnology (662)

Phone

484-453-3300

Address

10 NORTH HIGH STREET, WEST CHESTER, PA

Employee

Twitter

Next Earnings Date

2025-03-11

Latest SEC Filings

VRCA's Discussions on Twitter

Compare VRCA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRCA Verrica Pharmaceuticals Inc	0.5848	55.59M	5.12M	-67.00M	-38.94M	-1.47
VRTX Vertex Pharmaceuticals Inc	440.87	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	509.72	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	309.70	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	542.15	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	247.08	28.51B	3.81B	-644.79M	-669.77M	-6.24

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy
Mar-22-23	Initiated	Jefferies	Buy
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-14-21	Initiated	RBC Capital Mkts	Outperform
Dec-24-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy
Jun-24-20	Initiated	Northland Capital	Outperform
Mar-24-20	Initiated	Needham	Buy
Feb-21-19	Initiated	H.C. Wainwright	Buy

View All

Verrica Pharmaceuticals Inc Stock (VRCA) Latest News

Jun 18, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest - Defense World

Jun 18, 2025

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results - Barchart.com

Jun 18, 2025

Jun 16, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Hold” by Brokerages - Defense World

Jun 16, 2025

Jun 13, 2025

Shareholders May Not Overlook Verrica Pharmaceuticals Insiders Selling US$1.1m In Stock - simplywall.st

Jun 13, 2025

Jun 12, 2025

Verrica Pharmaceuticals amends credit agreement By Investing.com - Investing.com South Africa

Jun 12, 2025

Verrica Pharmaceuticals Amends Credit Agreement with OrbiMed - TipRanks

Jun 12, 2025

Verrica Pharmaceuticals amends credit agreement - Investing.com

Jun 12, 2025

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic? - Yahoo Finance

Jun 12, 2025

Jun 10, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% – Here’s Why - Defense World

Jun 10, 2025

Jun 05, 2025

Verrica Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 05, 2025

May 30, 2025

Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN

May 30, 2025

May 28, 2025

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York - GlobeNewswire

May 28, 2025

Verrica Pharmaceuticals CEO Reveals Dermatology Pipeline Updates at Jefferies Healthcare Conference - Stock Titan

May 28, 2025

May 25, 2025

Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded at Wall Street Zen - Defense World

May 25, 2025

Brokerages Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Target Price at $8.00 - Defense World

May 25, 2025

May 24, 2025

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline - MSN

May 24, 2025

May 22, 2025

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH - MSN

May 22, 2025

May 21, 2025

Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail

May 21, 2025

May 20, 2025

Verrica Pharmaceuticals’ SWOT analysis: stock faces cash crunch amid YCANTH growth - Investing.com Canada

May 20, 2025

Needham & Company LLC Reiterates “Hold” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World

May 16, 2025

May 15, 2025

Verrica signals sustainable growth trajectory as YCANTH revenues surpass $3M and Phase 3 milestone looms - MSN

May 15, 2025

RBC Capital Reaffirms Their Hold Rating on Verrica Pharmaceuticals (VRCA) - The Globe and Mail

May 15, 2025

May 14, 2025

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update - MSN

May 14, 2025

Verrica Pharmaceuticals (VRCA) Sees Q1 Revenue Growth Driven by YCANTH - GuruFocus

May 14, 2025

Verrica Pharmaceuticals (VRCA) Receives Hold Rating from Needham - GuruFocus

May 14, 2025